3.80
price up icon3.26%   0.12
pre-market  Pre-market:  3.71   -0.09   -2.37%
loading
Voyager Therapeutics Inc stock is traded at $3.80, with a volume of 571.43K. It is up +3.26% in the last 24 hours and down -8.21% over the past month. Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
See More
Previous Close:
$3.68
Open:
$3.71
24h Volume:
571.43K
Relative Volume:
0.84
Market Cap:
$229.60M
Revenue:
$40.37M
Net Income/Loss:
$-119.72M
P/E Ratio:
-1.8626
EPS:
-2.0402
Net Cash Flow:
$-135.06M
1W Performance:
+0.93%
1M Performance:
-8.21%
6M Performance:
-9.09%
1Y Performance:
+27.09%
1-Day Range:
Value
$3.71
$3.895
1-Week Range:
Value
$3.36
$3.895
52-Week Range:
Value
$2.645
$5.55

Voyager Therapeutics Inc Stock (VYGR) Company Profile

Name
Name
Voyager Therapeutics Inc
Name
Phone
857-259-5340
Name
Address
75 HAYDEN AVENUE, LEXINGTON, MA
Name
Employee
141
Name
Twitter
@VoyagerTx
Name
Next Earnings Date
2026-05-05
Name
Latest SEC Filings
Name
VYGR's Discussions on Twitter

Compare VYGR vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
VYGR icon
VYGR
Voyager Therapeutics Inc
3.80 222.35M 40.37M -119.72M -135.06M -2.0402
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
434.52 110.03B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
638.88 67.37B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
806.46 50.76B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
297.45 40.12B 4.29B 577.22M 641.34M 4.2086
RVMD icon
RVMD
Revolution Medicines Inc
151.56 32.68B 742.00K -1.37B -1.07B -7.0731

Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-10-25 Initiated Cantor Fitzgerald Overweight
Dec-02-24 Initiated Citigroup Buy
Nov-29-24 Resumed Wedbush Outperform
Oct-16-24 Initiated Leerink Partners Outperform
Mar-26-24 Initiated Guggenheim Buy
Mar-19-24 Initiated H.C. Wainwright Buy
Mar-07-24 Initiated Citigroup Buy
Jan-02-24 Upgrade Wells Fargo Equal Weight → Overweight
May-10-23 Initiated Truist Buy
Mar-10-23 Initiated Oppenheimer Outperform
Oct-07-21 Upgrade Robert W. Baird Neutral → Outperform
Feb-26-21 Downgrade Robert W. Baird Outperform → Neutral
Feb-03-21 Downgrade BTIG Research Buy → Neutral
Feb-03-21 Downgrade Wedbush Outperform → Neutral
Dec-24-20 Downgrade Cantor Fitzgerald Overweight → Neutral
Dec-23-20 Downgrade Raymond James Outperform → Mkt Perform
Nov-11-20 Downgrade Oppenheimer Outperform → Perform
Nov-10-20 Downgrade Raymond James Strong Buy → Outperform
Nov-10-20 Downgrade Wells Fargo Overweight → Equal Weight
Mar-19-20 Initiated The Benchmark Company Buy
Feb-06-20 Initiated Oppenheimer Outperform
Nov-15-18 Upgrade Raymond James Outperform → Strong Buy
Sep-10-18 Resumed BTIG Research Buy
Sep-10-18 Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-04-18 Initiated H.C. Wainwright Buy
Mar-12-18 Downgrade Evercore ISI Outperform → In-line
Mar-12-18 Downgrade Wedbush Outperform → Neutral
Feb-02-18 Initiated Morgan Stanley Overweight
Nov-28-17 Resumed Piper Jaffray Overweight
Oct-31-17 Initiated Robert W. Baird Outperform
Oct-27-17 Initiated Canaccord Genuity Buy
Oct-23-17 Reiterated Stifel Buy
Oct-12-17 Initiated Raymond James Outperform
Aug-17-17 Initiated Evercore ISI Outperform
Jul-28-17 Resumed Stifel Buy
View All

Voyager Therapeutics Inc Stock (VYGR) Latest News

pulisher
May 22, 2026

Voyager Therapeutics Inc. (VYGR) Q1 2026 Earnings: Narrowed Loss Meets Optimism in Gene Therapy PipelineEPS Consistency Score - Newser

May 22, 2026
pulisher
May 22, 2026

Voyager Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Market ResponseNet Income Trends - Newser

May 22, 2026
pulisher
May 22, 2026

Voyager Therapeutics (VYGR) Shares Rebound 4.76% as Biotech Sector Shows StrengthCrowd Risk Alerts - Newser

May 22, 2026
pulisher
May 20, 2026

- Insider Monkey

May 20, 2026
pulisher
May 20, 2026

What Voyager Therapeutics Inc (VYGR) Has Gained on Its Therapy Programs - Insider Monkey

May 20, 2026
pulisher
May 18, 2026

Voyager Therapeutics (VYGR) accounting officer reports initial share and option holdings - Stock Titan

May 18, 2026
pulisher
May 17, 2026

The one question every Voyager Therapeutics VYGR investor should ask Bullish Sentiment 20260510High Attention Stocks - Newser

May 17, 2026
pulisher
May 15, 2026

VYGR (NASDAQ: VYGR) affiliate files Form 144 to sell 25,000 shares - Stock Titan

May 15, 2026
pulisher
May 15, 2026

EcoR1 and Oleg Nodelman report 0 shares in Voyager (NASDAQ: VYGR) amendment - Stock Titan

May 15, 2026
pulisher
May 15, 2026

Armistice Capital (VYGR) reports 3.5M shares, 5.87% stake in Voyager - Stock Titan

May 15, 2026
pulisher
May 15, 2026

Voyager Therapeutics (NASDAQ: VYGR) affiliate files to sell 9,406 shares - Stock Titan

May 15, 2026
pulisher
May 15, 2026

Wedbush Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $8 - Moomoo

May 15, 2026
pulisher
May 14, 2026

TradingKey - TradingKey

May 14, 2026
pulisher
May 14, 2026

VYGR Technical Analysis | Trend, Signals & Chart Patterns | VOYAGER THERAPEUTICS INC (NASDAQ:VYGR) - ChartMill

May 14, 2026
pulisher
May 13, 2026

Voyager presents preclinical data for Alzheimer’s gene therapy By Investing.com - Investing.com India

May 13, 2026
pulisher
May 13, 2026

Voyager Therapeutics (VYGR) Reports Positive Findings for Alzhei - GuruFocus

May 13, 2026
pulisher
May 13, 2026

VYGR Secures Mission Management Contract for ISS Research - GuruFocus

May 13, 2026
pulisher
May 13, 2026

Voyager presents preclinical data for Alzheimer’s gene therapy - Investing.com UK

May 13, 2026
pulisher
May 13, 2026

Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026 - The Manila Times

May 13, 2026
pulisher
May 13, 2026

Voyager Therapeutics Advances VY1706 Gene Therapy for Alzheimer's Disease with IND Application on Track for Q2 2026 - Quiver Quantitative

May 13, 2026
pulisher
May 13, 2026

Voyager Therapeutics Presents Three-Month GLP Toxicology Data For VY1706 And Provides Updates On Gene Therapy Pipeline - marketscreener.com

May 13, 2026
pulisher
May 11, 2026

CCORF Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $12 - Moomoo

May 11, 2026
pulisher
May 10, 2026

The one question every Voyager Therapeutics (VYGR) investor should ask (Bullish Sentiment) 2026-05-10Social Momentum Signals - newser.com

May 10, 2026
pulisher
May 09, 2026

Voyager Therapeutics Announces CFO Resignation and Finance Leadership Changes - TipRanks

May 09, 2026
pulisher
May 09, 2026

Voyager Therapeutics (NASDAQ:VYGR) Rating Lowered to Sell at Wall Street Zen - MarketBeat

May 09, 2026
pulisher
May 09, 2026

Voyager Therapeutics Warns of Broad Risk Exposure and Uncertain Outlook in Latest SEC Filings - TipRanks

May 09, 2026
pulisher
May 08, 2026

Voyager Therapeutics stock (US92916U1025): Q1 2026 results and pipeline updates drive sentiment - AD HOC NEWS

May 08, 2026
pulisher
May 08, 2026

Voyager Therapeutics (VYGR) reports Q1 loss, misses revenue estimates - MSN

May 08, 2026
pulisher
May 08, 2026

Voyager Therapeutics: Q1 Earnings Snapshot - theheraldreview.com

May 08, 2026
pulisher
May 07, 2026

Voyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance

May 07, 2026
pulisher
May 07, 2026

Alzheimer’s gene therapy moves toward human testing as cash lasts into 2028 - Stock Titan

May 07, 2026
pulisher
May 07, 2026

Voyager Therapeutics (Nasdaq: VYGR) posts Q1 2026 loss and advances tau drugs - Stock Titan

May 07, 2026
pulisher
May 07, 2026

Voyager Therapeutics (Nasdaq: VYGR) trims Q1 2026 loss, holds $171.7M cash - Stock Titan

May 07, 2026
pulisher
May 07, 2026

Voyager Reports First Quarter 2026 Financial and Operating Results - marketscreener.com

May 07, 2026
pulisher
May 06, 2026

VOYAGER THERAPEUTICS, INC. (VYGR) - MSN

May 06, 2026
pulisher
May 05, 2026

Voyager Therapeutics CFO resigns; Robin Swartz takes financial charge - MSN

May 05, 2026
pulisher
May 05, 2026

The key driver behind Voyager Therapeutics (VYGR) revenue growth | Q4 2025: Better Than ExpectedDividend Report - Newser

May 05, 2026
pulisher
May 04, 2026

MSN Money - MSN

May 04, 2026
pulisher
May 02, 2026

Voyager Therapeutics Inc (VYGR) - MSN

May 02, 2026
pulisher
May 01, 2026

Voyager Therapeutics Inc expected to post a loss of 53 cents a shareEarnings Preview - TradingView

May 01, 2026
pulisher
May 01, 2026

Voyager Therapeutics (VYGR) Stock: Support Breakdown Risk | Q4 2025: EPS Beats ForecastsEBITDA Estimate Trend - Newser

May 01, 2026
pulisher
Apr 30, 2026

H.C. Wainwright Reaffirms Their Buy Rating on Voyager Therapeutics (VYGR) - The Globe and Mail

Apr 30, 2026
pulisher
Apr 29, 2026

H.C. Wainwright Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $25 - Moomoo

Apr 29, 2026

Voyager Therapeutics Inc Stock (VYGR) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$29.96
price down icon 2.98%
$106.24
price down icon 3.00%
$92.14
price up icon 1.33%
$54.50
price up icon 1.77%
ONC ONC
$310.25
price up icon 0.20%
$151.56
price down icon 1.41%
Cap:     |  Volume (24h):